US Patent

US11529362 — Physiologically balanced injectable formulations of fosnetupitant

Formulation · Assigned to Helsinn Healthcare SA · Expires 2037-06-02 · 11y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects physiologically balanced injectable formulations of fosnetupitant and its pharmaceutically acceptable salts.

USPTO Abstract

Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.

Drugs covered by this patent

fosnetupitant-chloride-hydrochloride (FOSNETUPITANT CHLORIDE HYDROCHLORIDE)

Patent Metadata

Patent number: US11529362
Jurisdiction: US
Classification: Formulation
Expires: 2037-06-02
Drug substance claim: No
Drug product claim: Yes
Assignee: Helsinn Healthcare SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.